Biogen

Founded in 1978, Biogen is a global biotechnology leader committed to transforming the lives of patients through groundbreaking science. With a legacy of innovation spanning over four decades, Biogen focuses on discovering, developing, and delivering first-in-class therapies that address some of the world’s most complex and devastating diseases.

At the heart of Biogen’s mission is a deep understanding of human biology. By leveraging multiple scientific modalities, the company aims to deliver treatments that not only push the boundaries of medical research but also achieve superior outcomes for patients. Biogen’s approach combines bold, science-driven innovation with a strategic focus on long-term value—ensuring sustainable growth for shareholders while improving global health.

Biogen employs approximately 7,000 people worldwide, fostering a culture of collaboration and scientific excellence. Its global headquarters in Cambridge, Massachusetts houses cutting-edge research operations, placing it in one of the most vibrant biotech ecosystems in the world. The company’s international headquarters in Baar, Switzerland, along with manufacturing sites in North Carolina and Solothurn, further strengthen its global capabilities.

Through a direct presence in 30 countries and a distribution network spanning more than 50 additional markets, Biogen ensures that its therapies reach patients around the globe. This broad reach reflects the company’s dedication to making a lasting impact in the lives of those affected by neurological, neurodegenerative, and rare diseases.

Biogen’s commitment to science, patient-centricity, and global health continues to position it as a trusted innovator in biotechnology. As the company looks to the future, it remains focused on delivering transformative therapies, expanding access to care, and driving positive change in communities around the world.